Proton radiotherapy for treating the most common carcinomas

Sas-Korczyńska, Beata; Jakubowicz, Jerzy; Reinfuss, Marian

doi:10.5603/njo.2016.0070

Cited by 1 publication

(1 citation statement)

References 101 publications

(138 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiotherapy has undergone remarkable transformation in the field of treatment precision [43]. Progress from 2D radiotherapy and imaging to image guided, dynamic 3D irradiation techniques and molecular imaging, enables us to spare organs at risk (OAR) and escalate radiation dose inside target volumes [44,45].…”

Section: Bone Marrow Sparing Rtmentioning

confidence: 99%

Bone marrow sparing RT in era of immunotherapy

Kuncman¹,

Pietrzykowska-Kuncman²,

Danielska³

et al. 2018

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

Recent advances in the field of immunotherapy have changed the perception of cancer treatment to complex model with host immunity in the spotlight. Potential synergy of immunotherapy drugs [aiming cytotoxic T cell antigen 4 (CTLA-4) or programmed cell death-1/ligand (PD-1/PD-L1)] and radiotherapy (RT) have established basis for ongoing clinical trials testing combined treatment. It was shown that complete blood cell counts (CBC) parameters may correlate with cancer survival, toxicity and outcomes of treatment. Therefore, reduction of hematologic toxicity of cancer treatment may gain in significance. Modern dose delivery techniques compromise dose reduction in critical organs (like bone marrow-BM) with adequate irradiation of target volumes. In addition, usage of modern imaging like positron emission tomography (PET), magnetic resonance imaging (MRI) allows to divide the volume of BM to active and inactive one. In this review, we discuss the synergy of RT and immunity and techniques of Bone Marrow Sparing RT (BMS-RT).

show abstract

Section: Bone Marrow Sparing Rtmentioning

confidence: 99%